Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
2 vistas
• 07/29/23
0
0
Empotrar
administrator
Suscriptores
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios